Literature DB >> 9689987

Frontonasal dysplasia with optic disc anomalies and other midline craniofacial defects: a report of six cases.

M M Lees1, P Hodgkins, W Reardon, D Taylor, R Stanhope, B Jones, R Hayward, A D Hockley, M Baraitser, R M Winter.   

Abstract

The association of optic disc abnormalities with basal encephaloceles, specifically of the sphenoethmoidal type, and midline facial clefts has rarely been reported, although the association of midline facial clefts with encephaloceles is well described. We now report six cases of children, three males and three females, presenting with a sphenoethmoidal encephalocele, optic disc anomalies, midline facial clefting, hypertelorism, complete or partial agenesis of the corpus callosum, and endocrinological disturbances, including diabetes insipidus and pituitary dysfunction. This report underlines the importance of careful ophthalmic and endocrinological investigation of children with midline clefts associated with basal encephaloceles. These cases may represent a distinct entity within the spectrum of frontonasal dysplasia.

Entities:  

Mesh:

Year:  1998        PMID: 9689987     DOI: 10.1097/00019605-199807000-00001

Source DB:  PubMed          Journal:  Clin Dysmorphol        ISSN: 0962-8827            Impact factor:   0.816


  2 in total

1.  Disruption of ALX1 causes extreme microphthalmia and severe facial clefting: expanding the spectrum of autosomal-recessive ALX-related frontonasal dysplasia.

Authors:  Elif Uz; Yasemin Alanay; Dilek Aktas; Ibrahim Vargel; Safak Gucer; Gokhan Tuncbilek; Ferdinand von Eggeling; Engin Yilmaz; Ozgur Deren; Nicole Posorski; Hilal Ozdag; Thomas Liehr; Sevim Balci; Mehmet Alikasifoglu; Bernd Wollnik; Nurten A Akarsu
Journal:  Am J Hum Genet       Date:  2010-05-06       Impact factor: 11.025

2.  The Syndrome of Frontonasal Dysplasia, Callosal Agenesis, Basal Encephalocele, and Eye Anomalies - Phenotypic and Aetiological Considerations.

Authors:  Antonio Richieri-Costa; Maria Leine Guion-Almeida
Journal:  Int J Med Sci       Date:  2004-03-10       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.